Selected article for: "antibiotic treatment and rifampicin treatment"

Author: Groeneveld, Geert H; van der Reyden, Tanny J; Joosten, Simone A; Bootsma, Hester J; Cobbaert, Christa M; de Vries, Jutte J C; Kuijper, Ed J; van Dissel, Jaap T
Title: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial
  • Document date: 2019_5_18
  • ID: 19ueli6e_10
    Snippet: Patients were randomized (2:1) between the intervention group and the control group, using a prepared single randomization list. This list was generated and the study patients assigned by independent persons. Since blinding of rifampicin treatment (due to orange secretions) is impossible, this study was open label. The intervention group was treated with 600 mg of rifampicin q12h intravenously for 48 h, in combination with a b-lactam antibiotic. .....
    Document: Patients were randomized (2:1) between the intervention group and the control group, using a prepared single randomization list. This list was generated and the study patients assigned by independent persons. Since blinding of rifampicin treatment (due to orange secretions) is impossible, this study was open label. The intervention group was treated with 600 mg of rifampicin q12h intravenously for 48 h, in combination with a b-lactam antibiotic. Rifampicin was to be given before the b-lactam antibiotic. b-Lactam antibiotic treatment had to be added to the intervention treatment because this is prescribed in current guidelines and rifampicin-resistant mutants readily appear with rifampicin monotherapy. 19 The control group was treated with a b-lactam antibiotic (without rifampicin).

    Search related documents:
    Co phrase search for related documents